Recent 8-K filings for AIDX

• September 10, 2026, 4:10 PM ET regulatory materiality 0.75 negative item 3.01

  20/20 Biolabs gets Nasdaq equity non-compliance notice; delisting risk

  On Sept 3, 2026, Nasdaq notified 20/20 Biolabs of non-compliance with $2.5M stockholders' equity rule; reported equity $1.62M.

• August 17, 2026, 4:05 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  20/20 BioLabs Q2 revenue up 37% to $0.7M; OneTest revenue up 47%

  Q2 2026 total revenue $0.7M, up 36.5% YoY; OneTest revenue $0.7M, up 47.1%, 95.3% of total.

• July 22, 2026, 4:45 PM ET other material materiality 0.75 negative item 1.01item 3.01item 9.01

  20/20 Biolabs enters standstill with Streeterville; receives Nasdaq bid price deficiency notice

  Standstill agreement with Streeterville: 120-day forbearance on conversion of Series E preferred unless stock price >10% above Nasdaq Minimum Price.

• May 20, 2026, 4:10 PM ET earnings materiality 0.70 negative item 2.02item 9.01 ◈ Earnings Releases

  20/20 BioLabs Q1 revenue $0.4M, net loss $2.2M; expects Q2 rebound from firefighter programs

  Q1 revenue $0.4M vs $0.6M YoY; net loss $2.2M vs $0.8M; gross margin 17.8% vs 29.9%.

• April 28, 2026, 7:59 PM ET other material materiality 0.85 negative item 1.01item 9.01

  20/20 Biolabs cuts warrant exercise price to $2.25, from $11.42/$8.00

  On April 23, 2026, amended Streeterville warrants lowering exercise price to $2.25/share.

• April 1, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  20/20 BioLabs FY 2025 revenue $2.0M (+17%); gross margin expands; $5M private placement

  Revenue $2.0M (+17% YoY); gross profit $0.6M (+68%); gross margin 29.6% vs 20.6%.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.43 · Most common event other

2 positive 4 negative 6 neutral

source · AIDX on sec.gov